Search research articles
Contact Us
Filters
Showing results (1-10 of 62) with videos related to
Page
of 7
Sort By:
Current Oncology Reports
|
November 29, 2018
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Ciara L Freeman, Laurie Sehn
British Journal of Haematology
|
May 20, 2020
COVID-19 and myeloma: what are the implications for now and in the future?
Ciara L Freeman, Joseph Mikhael
Current Hematologic Malignancy Reports
|
February 10, 2016
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Ciara L Freeman, John G Gribben
British Journal of Haematology
|
May 10, 2018
A tale of two antibodies: obinutuzumab versus rituximab
Ciara L Freeman, Laurie H Sehn
Blood
|
September 21, 2023
CARs put age in the rearview mirror
Ciara L Freeman, Frederick L Locke
Hematology/Oncology Clinics of North America
|
June 27, 2020
Initial Treatment of High Tumor Burden Follicular Lymphoma
Ciara L Freeman, Laurie H Sehn
Expert Review of Hematology
|
January 26, 2012
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Ciara L Freeman, Ronan Swords, Francis J Giles
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Fitness and frailty in myeloma
Charlotte Pawlyn, Abdullah M Khan, Ciara L Freeman
Cancers
|
March 13, 2024
Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment
Stefaan W Verbruggen, Ciara L Freeman, Fiona E Freeman
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Treatment of older adult or frail patients with multiple myeloma
Shakira J Grant, Ciara L Freeman, Ashley E Rosko
Page
of 7
Search research articles
Search
Showing results (1-10 of 62) with videos related to
Sort By:
Page
of 7
Current Oncology Reports
|
November 29, 2018
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Ciara L Freeman, Laurie Sehn
British Journal of Haematology
|
May 20, 2020
COVID-19 and myeloma: what are the implications for now and in the future?
Ciara L Freeman, Joseph Mikhael
Current Hematologic Malignancy Reports
|
February 10, 2016
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Ciara L Freeman, John G Gribben
British Journal of Haematology
|
May 10, 2018
A tale of two antibodies: obinutuzumab versus rituximab
Ciara L Freeman, Laurie H Sehn
Blood
|
September 21, 2023
CARs put age in the rearview mirror
Ciara L Freeman, Frederick L Locke
Hematology/Oncology Clinics of North America
|
June 27, 2020
Initial Treatment of High Tumor Burden Follicular Lymphoma
Ciara L Freeman, Laurie H Sehn
Expert Review of Hematology
|
January 26, 2012
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?
Ciara L Freeman, Ronan Swords, Francis J Giles
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Fitness and frailty in myeloma
Charlotte Pawlyn, Abdullah M Khan, Ciara L Freeman
Cancers
|
March 13, 2024
Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment
Stefaan W Verbruggen, Ciara L Freeman, Fiona E Freeman
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Treatment of older adult or frail patients with multiple myeloma
Shakira J Grant, Ciara L Freeman, Ashley E Rosko
Page
of 7